Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 133, Issue -, Pages 329-339Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2017.03.083
Keywords
NSCLC; EGFR T790M; Resistance; Inhibitors; Pyrimidine
Categories
Funding
- National Natural Science Foundation of China [81402788]
- Cultivation Project of Youth Tech stars, Dalian, China [2016RQ043]
Ask authors/readers for more resources
Potential new EGFR(T790M) inhibitors comprised of structurally modified diphenylpyrimidine derivatives bearing a morpholine functionality (Mor-DPPYs) were used to improve the activity and selectivity of gefitinib-resistant non-small cell lung cancer (NSCLC) treatment. This led to the identification of inhibitor 10c, which displayed high activity against EGFR(T790M/L858R) kinase (IC50 = 0.71 nM) and repressed H1975 cell replication harboring EGFR(T790M) mutations at a concentration of 0.037 mu M. Inhibitor 10c demonstrated high selectivity (SI = 631.9) for T790M-containing EGFR mutants over wild type EGFR, suggesting that it will cause less side effects. Moreover, this compound also shows promising antitumor efficacy in a murine EGFR(T790M/L858R)-driven H1975 xenograft model without affecting body weight. This study provides new potential lead compounds for further development of anti-NSCLC drugs. (C) 2017 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available